Quantcast

Latest Monoclonal antibodies Stories

2014-10-10 12:24:18

Investigators' Oral and Poster Presentations Highlight Canine Lymphoma Antibody Programs KANSAS CITY, Kan., Oct. 10, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced its first appearance at the Annual Veterinary Cancer Society meeting this weekend in St. Louis, MO. Investigators presented data on monoclonal...

2014-10-08 12:28:53

Patient Shares For Newer Alternative MOA Agents Are Also Expected To Grow In The Next Six Months, According To Findings From Decision Resources Group BURLINGTON, Mass., Oct. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that despite the increasing percentage of rheumatoid arthritis (RA) patients treated with agents with a newer mechanism of action (MOA), three-quarters of DMARD-failure RA patients who are naive to biologics/Pfizer's Xeljanz are still initiated on tumor necrosis...

2014-10-08 08:28:04

Primary Efficacy Analysis Demonstrates Clinical Equivalence THOUSAND OAKS, Calif., Oct. 8, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced its Phase 3 study evaluating efficacy and safety of biosimilar candidate ABP 501 compared with Humira(®) (adalimumab) in patients with moderate-to-severe plaque psoriasis met its primary endpoint. The primary endpoint was the Psoriasis Area and Severity Index (PASI) percent improvement from baseline to week 16 of treatment. At week 16,...

2014-10-07 23:02:27

New cutting-edge report “Global Cancer Monoclonal Antibodies Market & Pipeline Insight” worked out by Kuick Research is now available at MarketPublishers.com. London, UK (PRWEB) October 07, 2014 Over the last few decades, the researchers have increased their knowledge about the human immune system, which has resulted in the achievement of considerable amount of regulatory milestones during the period. The use of monoclonal antibodies (mAbs) for the treatment of cancer has grown...

2014-10-07 12:28:28

Physicians Indicate that Switching of Currently Treated Patients to Biosimilar Infliximab Is Likely to be Limited, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed rheumatologists in France, Germany and the United States expect to prescribe biosimilar infliximab within one year of launch if the biosimilar is priced at a net discount of 15-30 percent to Remicade and has demonstrated...

2014-10-06 08:28:13

-- Polyarticular juvenile idiopathic arthritis (JIA) occurs in approximately 25 percent of all JIA patients NORTH CHICAGO, Ill., Oct. 6, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the HUMIRA indication for moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) to reducing signs and symptoms in patients ages 2 and older. HUMIRA was approved in the United States in 2008 for...

2014-10-03 16:24:37

AbGenomics raised new fund for advancing its mid-stage clinical trials LOS ALTOS, Calif., Oct. 3, 2014 /PRNewswire-iReach/ -- AbGenomics will use the proceeds to continue advancing its therapeutic antibodies for autoimmune diseases and cancers in clinical development. The company is focusing on conducting Phase II clinical trials for its lead drug candidate AbGn-168H, a humanized monoclonal antibody that induces apoptosis of pathogenic activated T cells for the treatment of...

2014-10-03 16:24:22

SAN DIEGO, Oct. 3, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that China Oncology Focus Limited, an Affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharma), a public biopharmaceutical company listed on the main board of Hong Kong Stock Exchange (0950) with over 20 years of operation in China's pharmaceutical industry, has...

2014-10-01 23:02:26

The Firm is evaluating legal claims on behalf of individuals who allegedly suffered serious Xolair side effects, including heart attacks, mini-strokes, pulmonary hypertension, and blood clots in the lungs and veins. New York, New York (PRWEB) October 01, 2014 The nationwide law firm of Bernstein Liebhard LLP is now evaluating Xolair side effect claims (http://www.consumerinjurylawyers.com/xolair-lawsuit) on behalf of individuals who allegedly suffered serious health issues that may be...

2014-10-01 16:27:17

Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present several studies related to brodalumab, Enbrel(®) (etanercept) and ABP 501 (adalimumab biosimilar) at the 23(rd) Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam, Oct. 8-12, 2014. These data reinforce Amgen's continued commitment to...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related